Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES UPSIZE AND CLOSING OF SECOND AND FINAL TRANCHE OF NON-BROKERED UNIT PRIVATE PLACEMENT

Ventripoint Diagnostics Ltd., subject to approval of TSX Venture Exchange, has increased the size and closed the second and final tranche of its previously announced non-brokered private placement of up to 4,024,250 units at a price of 10 cents per unit. The first tranche of the offering closed on Sept. 8, 2026, with the issuance of 1.8 million units (see news release dated Sept. 8, 2026). The second and final tranche of the offering has closed with the issuance of an additional 2,224,250 units. The corporation issued an aggregate of $222,425 of units pursuant to the offering.

Each unit comprises one common share of the corporation and one common share purchase warran.

Each whole warrant will entitle the holder thereof to purchase one common share at a price of 14 cents for a period of 24 months from the closing of the offering. The corporation reserves the right to accelerate the warrant expiry period upon 30 days notice if the common shares trade at 30 cents for a period of 10 consecutive days, including days where no trades occur.

The corporation will use the proceeds of the offering to finance commercialization initiatives, advancement of Ventripoint's core diagnostic technology platform and working capital.

The offering is a related party transaction within the meaning of TSX-V Policy 5.9 and Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions, for the corporation as insiders of the corporation subscribed for an aggregate of 460,000 units on the same terms as arm's-length subscribers. The corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101, as the corporation is not listed on a specified market and the fair market value of the participation in the transactions by insiders does not exceed 25 per cent of the market capitalization of the corporation, as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2.5-million. The corporation did not file a material change report in respect of the related party transaction at least 21 days before the closing of the offering, which the corporation deems reasonable in the circumstances in order to complete the transaction.

All securities issued and issuable pursuant to the offering are subject to a hold period of four months plus one day from the date of closing of the offering. The offering is subject to final approval by the exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.